Pharmaceutical Development and Manufacturing — The New Post-Pandemic Realities

  • Discussing how the business model change accelerates
  • Highlighting transformation needs in business setup, technology and ways of working
  • Impact on Development and Manufacturing of different modalities
  • How does Bayer gets prepared for such opportunities and challenges?

Wolfram Carius
EVP Pharmaceuticals
Bayer AG

Prof. Wolfram Carius is the EVP Pharmaceuticals at Bayer AG and is a member of the Executive Committee for Bayer Pharmaceuticals. He is based in Berlin, Germany. Prior to joining Bayer, Wolfram was a corporate senior vice president and member of the global leadership team at Sanofi Genzyme for nearly three years. Before that, he worked for Boehringer Ingelheim from 1987 to the end of 2013, eventually becoming responsible for that company’s worldwide chemical, pharmaceutical, and biopharma production network. In his over 30 years in the pharmaceutical industry he has worked in Asia, South America and Europe. In 2009, the Biberach University of Applied Sciences awarded him the title of honorary professor in recognition for his long and exceptional service. He also holds a PhD in pharmaceutical biology and analytical phytochemistry from the University of Saarland, Germany.